Sanifit has bagged €72.2m in Spains largest private biotech fundraise.
Genfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor to Terns Pharmaceuticals Inc.
Life sciences venture capitalist Vesalius Biocapital III has announced the final close of the VBC III fund at €120m.
Erytech Pharma has inked a deal with SQZ Biotechnologies Inc. to develop new immune modulating therapies.
Sanofis and Regenerons IL-33 blocker REGN3500 met primary Phase II endpoint in asthma patients.
Karo Pharma AB announced it will acquire Trimb Holding AB for MSEK3,400 (€319.6m) and intends to carry out a Rights Issue of about MSEK 1,500 (€141m).
Deep Branch Biotechnology Ltd. from Nottingham has started a feasibility study with the British energy supplier Drax Group. The technology to be analysed converts carbon dioxide emitted by power stations into protein that could be used for feeding fish and livestock.
German GM proponents have taken action against discrimination of food products generated by gene editing.
Roche and US company Hesperos Inc have used human cancer and organ cells, placed in a 5-chamber microfluidic chip, to predict chemotherapy safety and efficacy preclinically.
Researchers from Israel and the UK have identified how the cytokine IL-23 triggers inflammatory bowel syndrome (IBD), which affects 1.6 million patients annually in the US alone.